Ads

You May Also Like

AnaptysBio Announces First-In-Human Dosing of ANB019

SAN DIEGO, April 06, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology ...

Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results

-- New drug applications for omadacycline accepted for priority review by FDA; PDUFA action ...